AP3140A - Production of polio virus at high titers for vaccine production - Google Patents

Production of polio virus at high titers for vaccine production

Info

Publication number
AP3140A
AP3140A AP2012006075A AP2012006075A AP3140A AP 3140 A AP3140 A AP 3140A AP 2012006075 A AP2012006075 A AP 2012006075A AP 2012006075 A AP2012006075 A AP 2012006075A AP 3140 A AP3140 A AP 3140A
Authority
AP
ARIPO
Prior art keywords
production
high titers
polio virus
vaccine
vaccine production
Prior art date
Application number
AP2012006075A
Other languages
English (en)
Other versions
AP2012006075A0 (en
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AP2012006075A0 publication Critical patent/AP2012006075A0/xx
Application granted granted Critical
Publication of AP3140A publication Critical patent/AP3140A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2012006075A 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production AP3140A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
EP09165620 2009-07-16
PCT/EP2010/059796 WO2011006823A1 (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Publications (2)

Publication Number Publication Date
AP2012006075A0 AP2012006075A0 (en) 2012-02-29
AP3140A true AP3140A (en) 2015-02-28

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006075A AP3140A (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Country Status (33)

Country Link
US (4) US8546123B2 (ru)
EP (1) EP2454364B1 (ru)
JP (1) JP5845178B2 (ru)
KR (1) KR101548790B1 (ru)
CN (1) CN102482647B (ru)
AP (1) AP3140A (ru)
AR (1) AR077314A1 (ru)
AU (1) AU2010272685B2 (ru)
BR (1) BR112012000942B8 (ru)
CA (1) CA2763091C (ru)
CO (1) CO6491042A2 (ru)
CU (1) CU20120006A7 (ru)
DK (1) DK2454364T3 (ru)
EA (1) EA020563B1 (ru)
ES (1) ES2484093T3 (ru)
HK (1) HK1164922A1 (ru)
HR (1) HRP20140597T1 (ru)
IL (1) IL217465A (ru)
MA (1) MA33429B1 (ru)
MX (1) MX2011012648A (ru)
MY (1) MY183385A (ru)
NZ (1) NZ596880A (ru)
PE (1) PE20120571A1 (ru)
PL (1) PL2454364T3 (ru)
PT (1) PT2454364E (ru)
RS (1) RS53377B (ru)
SG (1) SG177655A1 (ru)
SI (1) SI2454364T1 (ru)
SM (1) SMT201400079B (ru)
TN (1) TN2011000628A1 (ru)
TW (1) TWI477606B (ru)
WO (1) WO2011006823A1 (ru)
ZA (1) ZA201108271B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
PL2350268T3 (pl) 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
ES2484093T3 (es) 2009-07-16 2014-08-11 Crucell Holland B.V. Producción de poliovirus con títulos elevados para producción de vacunas
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN108588027A (zh) 2013-02-05 2018-09-28 乔治亚大学研究基金公司 用于病毒生产的细胞系和使用方法
BR112015021523A8 (pt) 2013-03-08 2021-06-29 Crucell Holland Bv composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
CN105121634B (zh) 2013-03-13 2019-07-26 易木农麦克斯有限公司 具有提高的病毒生产能力的细胞系及其生产方法
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
US10080793B2 (en) 2013-06-17 2018-09-25 De Staat der Nederlanden, vert, door de minister van VWS, Ministerie van Volksgezonheid, Welzijn en Sport Methods for the prevention of aggregation of viral components
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
JP6591461B2 (ja) 2014-06-17 2019-10-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 低温適応性ウイルス弱毒化（ｃａｖａ）および新規の弱毒化ポリオウイルス株
CN106661558B (zh) 2014-06-18 2020-07-10 易木农麦克斯有限公司 用于通过使用已缺失bst2基因功能的细胞系来促进病毒感染和增加病毒产生的方法
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
BR112017001177B1 (pt) * 2014-07-24 2022-05-24 Janssen Vaccines & Prevention B.V Método de purificação e de potenciação da liberação de poliovírus a partir de uma colheita de cultura celular bruta contendo poliovírus e uso de um detergente catiônico
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP3969046A1 (en) 2019-05-16 2022-03-23 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
JP2022551805A (ja) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) * 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
EP1553983A2 (en) * 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP2258850B1 (en) * 2002-12-17 2013-07-17 Crucell Holland B.V. Recominant viral-based malaria vaccins
EP1623023B1 (en) * 2003-05-09 2008-11-12 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20080193478A1 (en) 2004-08-27 2008-08-14 Rajesh Jain Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
AU2005293572B2 (en) * 2004-10-14 2011-08-04 Crucell Holland B.V. Malaria prime/boost vaccines
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
WO2008059041A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
ES2484093T3 (es) * 2009-07-16 2014-08-11 Crucell Holland B.V. Producción de poliovirus con títulos elevados para producción de vacunas
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
US20110027317A1 (en) 2011-02-03
CA2763091A1 (en) 2011-01-20
BR112012000942B1 (pt) 2020-10-27
AP2012006075A0 (en) 2012-02-29
US9022240B2 (en) 2015-05-05
MA33429B1 (fr) 2012-07-03
TWI477606B (zh) 2015-03-21
US20130052224A1 (en) 2013-02-28
MY183385A (en) 2021-02-18
TN2011000628A1 (en) 2013-05-24
MX2011012648A (es) 2012-01-12
PT2454364E (pt) 2014-07-04
IL217465A0 (en) 2012-02-29
AU2010272685A1 (en) 2011-12-08
CU20120006A7 (es) 2012-10-15
EA020563B1 (ru) 2014-12-30
AU2010272685B2 (en) 2015-02-26
CO6491042A2 (es) 2012-07-31
RS53377B (en) 2014-10-31
KR101548790B1 (ko) 2015-08-31
AR077314A1 (es) 2011-08-17
ES2484093T3 (es) 2014-08-11
HK1164922A1 (en) 2012-09-28
SMT201400079B (it) 2014-09-08
PE20120571A1 (es) 2012-06-06
JP2012532616A (ja) 2012-12-20
CA2763091C (en) 2019-07-23
NZ596880A (en) 2013-10-25
CN102482647B (zh) 2015-12-16
PL2454364T3 (pl) 2014-09-30
US20130273106A1 (en) 2013-10-17
WO2011006823A1 (en) 2011-01-20
EA201270173A1 (ru) 2012-06-29
BR112012000942B8 (pt) 2021-05-25
IL217465A (en) 2016-05-31
US20140242670A1 (en) 2014-08-28
BR112012000942A2 (pt) 2016-03-15
ZA201108271B (en) 2012-07-25
KR20120033334A (ko) 2012-04-06
DK2454364T3 (da) 2014-07-21
SG177655A1 (en) 2012-02-28
HRP20140597T1 (hr) 2014-09-12
TW201118173A (en) 2011-06-01
SI2454364T1 (sl) 2014-08-29
JP5845178B2 (ja) 2016-01-20
CN102482647A (zh) 2012-05-30
EP2454364B1 (en) 2014-04-23
US8546123B2 (en) 2013-10-01
EP2454364A1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
AP3140A (en) Production of polio virus at high titers for vaccine production
IL270661B (en) A method for preparing vlps that are plant histories
HUS1700002I1 (hu) Hepatitis C vírus replikációjának inhibitorai
HK1178165A1 (en) Novel inhibitors of hepatitis virus replication
EP2470189A4 (en) METHODS FOR PREPARING HEPATITIS C VIRUS PROTEASE INHIBITORS
ZA201202758B (en) Stabilising excipient for inactivated whole-virus vaccines
HK1166704A1 (zh) 利用用於鼻內給藥的疫苗預防流感的方法
EP2484378A4 (en) VACCINE COMPOSITION AGAINST HEPATITIS C VIRUS
PL2396032T3 (pl) Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
ZA201101645B (en) Process for prodcution of vaccines
GB0918679D0 (en) Influenza vaccine
EP2482843A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
EP2484757A4 (en) VIRUS FOR THE EXPRESSION OF ALPHA GALACTOSE EPITOPES AND METHOD FOR THE PRODUCTION OF A VACCINE
GB2467215B (en) Burkholderia components vaccine
EP2432885A4 (en) METHOD FOR INCREASING THE INFECTIOUSITY OF RETROVIRUSES
EP2424879A4 (en) INFLUENZA VACCINE
EP2488185A4 (en) INFECTIOUS TORQUE TENO VIRUS CLONE
HK1177692A1 (zh) 新的流感病毒
GB0714489D0 (en) Process for preparing viral vaccine
ZA201203862B (en) Dna vaccine against virus of yellow fever
GB0920319D0 (en) HPV vaccine
GB0903910D0 (en) Vaccine production